Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS in pancreatic cancer: new drugs on the horizon.

Cancer metastasis reviews - 1 Sept 2021

Bannoura Sahar F, Uddin Md Hafiz, Nagasaka Misako, Fazili Farzeen, Al-Hallak Mohammed Najeeb, Philip Philip A, El-Rayes Bassel, Azmi Asfar S

Abstract excerpt

Kirsten Rat Sarcoma (KRAS) is a master oncogene involved in cellular proliferation and survival and is the most commonly mutated oncogene in all cancers. Activating KRAS mutations are present in over 90% of pancreatic ductal adenocarcinoma (PDAC) cases and are implicated in tumor initiation and progression. Although KRAS is a critical oncogene, and therefore an important therapeutic target, its therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Pharmaceutical Preparations

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 34499267
DOI: 10.1007/s10555-021-09990-2
PMCID: PMC8556325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS in pancreatic cancer: new drugs on the horizon.PMID 34499267Read ↗

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).Semantic proximity Read ↗

Targeting KRAS mutations in pancreatic cancer: opportunities for future strategiesSemantic proximity Read ↗

KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Semantic proximity Read ↗

KRAS: the Achilles' heel of pancreas cancer biology.Semantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer.Semantic proximity Read ↗

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies.Semantic proximity Read ↗

Challenges in Ras therapeutics in pancreatic cancer.Semantic proximity Read ↗

KRAS Pathway-based Therapeutic Approaches in Pancreatic Cancer.Semantic proximity Read ↗

Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.Semantic proximity Read ↗

KRAS mutation in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.